Ascendis Pharma (NASDAQ: ASND) is a Copenhagen-headquartered biopharmaceutical company whose TransCon linker platform releases native peptide and small-molecule drugs at controlled rates from an inert prodrug scaffold, producing sustained pharmacokinetics with once-weekly and once-monthly dosing profiles that would otherwise require daily injection of the native molecule.
The commercial franchise anchored on three approved TransCon peptide products, with combined Q2 2026 product revenue of €315 million (+105% year-over-year). YORVIPATH (palopegteriparatide, TransCon parathyroid hormone peptide analog for chronic hypoparathyroidism) delivered €252 million on consistent U.S. new patient demand plus continued ex-U.S. global launch expansion with full reimbursement in additional markets. SKYTROFA (lonapegsomatropin, TransCon growth hormone peptide for pediatric growth hormone deficiency) delivered €55 million. YUVIWEL (navepegritide, TransCon C-type natriuretic peptide for achondroplasia) delivered €8 million in its first U.S. commercial quarter with more than 220 U.S. patient enrollments through July 31.
On Monday August 31, 2026, Ascendis and BioMarin announced a binding term sheet for a global settlement resolving all YUVIWEL patent disputes: Ascendis gets a worldwide non-exclusive license to continue commercializing navepegritide-related products; Ascendis pays 20% royalties on U.S. net sales and 18% on EU, South Korea, and Brazil sales through May 20, 2030; BioMarin dismisses the ITC Section 337 investigation and litigation in five countries. The settlement removes the largest overhang on the Ascendis stock and clears the achondroplasia commercial trajectory. Stories here cover TransCon platform advances, commercial performance, and pipeline. See [[yuviwel]], [[yorvipath]], and [[skytrofa]] for adjacent threads.
On September 7, 2026, Ascendis announced that the first sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP) in infants with achondroplasia aged 0 to under 2 years would be presented as a podium talk at the ESPE 2026 congress in Marseille on Tuesday September 8. The ESPE lineup also includes the HighLiGHts Phase 3 trial design for lonapegsomatropin across Turner syndrome, SHOX deficiency, small-for-gestational-age, and idiopathic short stature, plus hypoparathyroidism patient-reported-outcome data. The reACHin sentinel is the first look at TransCon CNP in the youngest achondroplasia population and follows the October 2025 EMA marketing authorization application, with an EU decision expected Q4 2026. See [[transcon-cnp]] for the navepegritide-specific thread.
Ascendis Pharma A/S (NASDAQ: ASND) presented Tuesday September 15, 2026 at 8:30 a.m. ET at the Morgan Stanley 24th Annual Global Healthcare Conference in New York in a fireside chat format. The presentation followed the ESPE 2026 congress podium delivery September 8 of first Week 52 sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, marketed as YUVIWEL in the U.S.) in 7 infants with achondroplasia aged 0 to under 2 years: 9.9 cm/year annualized growth velocity, +0.42 ACH-specific supine length Z-score, +3.15 mm sagittal foramen magnum increase, and no decompression surgeries at 100 μg/kg/week dosing. The Ascendis TransCon endocrinology franchise reached €315 million in combined Q2 2026 product revenue (+105% year-over-year): YORVIPATH (palopegteriparatide, PTH replacement) €252 million, SKYTROFA (lonapegsomatropin, growth hormone) €55 million, and YUVIWEL (navepegritide, CNP for achondroplasia) €8 million in the first U.S. commercial quarter. The August 31 Ascendis-BioMarin global settlement resolves the YUVIWEL patent overhang (20% U.S. royalties, 18% EU/South Korea/Brazil through May 2030; ITC Section 337 dismissed).
Ascendis Pharma A/S (NASDAQ: ASND) presented Thursday September 10, 2026 at the closing day of the ESPE 2026 congress in Marseille the trial-design abstract for HighLiGHts, a Phase 3 study of lonapegsomatropin (TransCon human growth hormone, a sustained-release growth hormone prodrug branded SKYTROFA in the U.S. and marketed for pediatric growth hormone deficiency since 2021) in children with short stature or growth failure due to Turner syndrome, SHOX deficiency, small-for-gestational-age (SGA), or idiopathic short stature. The four-indication combined trial design targets patients whose short stature is not attributable to growth hormone deficiency per se, expanding beyond the current SKYTROFA U.S. label for pediatric GHD. The presentation was one of several Ascendis ESPE items following the Tuesday September 8 podium delivery of first Week 52 sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP) in infants with achondroplasia. Ascendis reported €55 million in Q2 2026 SKYTROFA revenue alongside €252 million from YORVIPATH and €8 million from YUVIWEL, for a €315 million combined product-revenue quarter.
Ascendis Pharma A/S (NASDAQ: ASND) announced Wednesday September 9, 2026 first Week 52 sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, a sustained-release C-type natriuretic peptide prodrug branded YUVIWEL in the U.S. for ages ≥2 years) in 7 treatment-naïve, genetically confirmed infants with achondroplasia aged 0 to under 2 years (mean age 11.7 months). At 100 μg/kg/week once-weekly dosing, the sentinel cohort reached 9.9 cm/year annualized growth velocity through Week 52; ACH-specific supine length Z-score improved by +0.42 from baseline; mean sagittal foramen magnum diameter increased by +3.15 mm with all children stable or improved on the Achondroplasia Foramen Magnum Score, and no decompression surgeries during the treatment period. Safety: no injection-site reactions, no deaths, no fractures, no bone-related events, no symptomatic hypotension. No treatment-related adverse events were reported and no trial discontinuations occurred. Genevieve Baujat MD (Necker Hospital) presented the data as podium abstract FC4.6 on Tuesday September 8. Full reACHin double-blind enrollment is complete with a 52-week extension ongoing. YUVIWEL was FDA-approved February 2026 for ages ≥2 years; the EMA decision on achondroplasia is anticipated Q4 2026.
Ascendis Pharma A/S (NASDAQ: ASND) presented first sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, a sustained-release C-type natriuretic peptide prodrug branded YUVIWEL in the U.S. for achondroplasia in children ≥2 years) in infants aged 0 to under 2 years at the ESPE 2026 congress in Marseille on Tuesday September 8, 2026 (abstract FC4.6, 3:00-4:00 p.m. CEST podium session; Genevieve Baujat MD, Necker Hospital, presenting). The reACHin study completed target enrollment and extends navepegritide's tested age range down to infancy, the population most vulnerable to achondroplasia complications from cervicomedullary compression, foramen magnum stenosis, and delayed motor milestones. Additional ESPE presentations include the HighLiGHts Phase 3 trial design for lonapegsomatropin (TransCon hGH) across Turner syndrome, SHOX deficiency, small-for-gestational-age, and idiopathic short stature; two poster presentations on adolescent hypoparathyroidism patient-reported outcomes; and a systematic literature review on pediatric growth hormone deficiency prevalence. Ascendis' TransCon franchise generated €315 million in Q2 2026 product revenue (+105% year-over-year) with YUVIWEL contributing €8 million in its first U.S. commercial quarter.
Ascendis Pharma A/S (NASDAQ: ASND) announced Monday September 7, 2026 that the first sentinel-cohort data from the Phase 3 reACHin trial of navepegritide (TransCon CNP, a sustained-release CNP peptide prodrug) in infants with achondroplasia aged 0 to under 2 years will be presented as a podium talk at the European Society for Paediatric Endocrinology (ESPE) 2026 congress in Marseille, France (September 8-10). The reACHin presentation (FC4.6) is scheduled for Tuesday September 8, 3:00-4:00 p.m. CEST by Genevieve Baujat MD. Additional presentations include the HighLiGHts Phase 3 trial design for lonapegsomatropin (TransCon hGH) across Turner syndrome, SHOX deficiency, small-for-gestational-age, and idiopathic short stature; hypoparathyroidism patient-reported-outcome data from adolescents; and a systematic literature review on pediatric growth hormone deficiency prevalence. Ascendis submitted the TransCon CNP marketing authorization application to the EMA in October 2025 with an EU decision expected Q4 2026. Navepegritide is engineered to provide continuous CNP receptor stimulation without the peak-and-trough kinetics that constrained earlier vosoritide (Voxzogo) dosing.
Ascendis Pharma (NASDAQ: ASND) and BioMarin Pharmaceutical (NASDAQ: BMRN) announced Monday August 31, 2026 a binding term sheet for a global settlement and license agreement resolving all litigation and disputes related to YUVIWEL (navepegritide, TransCon C-type natriuretic peptide for achondroplasia and hypochondroplasia). Terms: BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction, and waives certain regulatory rights and exclusivities. Ascendis makes royalty payments to BioMarin of 20% on U.S. net sales and 18% on European Union, South Korea, and Brazil net sales from first commercial sale through May 20, 2030. BioMarin dismisses the pending U.S. International Trade Commission Section 337 investigation plus litigation in Brazil, Denmark, Germany, South Korea, and the U.S. Northern District of California. The settlement covers all current and potential YUVIWEL indications, including achondroplasia and hypochondroplasia, and removes the largest overhang on the Ascendis TransCon peptide platform.
BridgeBio Pharma (NASDAQ: BBIO) priced a 5,000,000-share secondary offering of common stock on Friday August 14, 2026 on behalf of selling stockholder KKR Genetic Disorder L.P. at the August 13 closing price of $81.21 per share on Nasdaq. The implied secondary-market proceeds to KKR total roughly $406 million. BridgeBio is not selling any shares and will not receive any of the proceeds; the transaction diversifies BridgeBio's institutional shareholder base as KKR reduces its position following a multi-year holding period. The offering is expected to close August 17, 2026 with William Blair, Goldman Sachs & Co. LLC, and KKR Capital Markets LLC as joint book-running managers. The BridgeBio commercial franchise includes infigratinib, the weekly-dosing FGFR inhibitor for achondroplasia that competes directly against BioMarin's Voxzogo (vosoritide, daily subcutaneous C-type natriuretic peptide analog) and Ascendis's newly-launched YUVIWEL (weekly TransCon C-type natriuretic peptide). The three-way competitive dynamic in pediatric achondroplasia now involves daily-injectable (Voxzogo), weekly-injectable peptide (YUVIWEL), and weekly-oral small-molecule (infigratinib) options, and the BridgeBio franchise is positioned at the small-molecule end of that spectrum. Although infigratinib is not itself a peptide analog, the achondroplasia commercial category is one of the fastest-growing peptide-adjacent pediatric-rare-disease indications following the July 8, 2026 New England Journal of Medicine publication of the Ascendis TRANSCEND trial results and the June 2026 YUVIWEL FDA approval.
Ascendis Pharma (NASDAQ: ASND) shares fell approximately 2.4% premarket Friday August 14, 2026 to $249.28 (compared to Thursday close of $255.46) despite reporting Q2 2026 EPS of $2.83 (beating the $1.51 analyst consensus by 87%) on revenue of $339.3 million (beating the $326.5 million consensus). Q2 2026 product revenue reached €315 million (+105% year-over-year) led by YORVIPATH (palopegteriparatide) at €252 million, SKYTROFA (lonapegsomatropin) at €55 million, and YUVIWEL (TransCon CNP for achondroplasia) at €8 million in its first US quarter with 220+ patient enrollments through July 31. The company ended Q2 2026 with €812 million in cash, no bank or convertible debt, and expects to generate more than €500 million in operating cash flow this year. The market response reflects investors balancing the substantive beat against the ongoing International Trade Commission (ITC) patent-infringement case brought by BioMarin Pharmaceutical (NASDAQ: BMRN) over the YUVIWEL launch. BioMarin owns U.S. Patent No. RE48,267 covering peptide analog variants including its FDA-approved Voxzogo (vosoritide). A first ITC opinion is expected in August 2026 following the March 26, 2026 Federal Circuit ruling in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. that a party cannot use voluntary dismissal to restart a statutory deadline it already missed. The case represents the first substantive peptide-vs-peptide patent battle in the achondroplasia commercial category.
Ascendis Pharma (NASDAQ: ASND) reported Thursday August 13, 2026 Q2 2026 financial results with product revenue of €315 million (+105% year-over-year). YORVIPATH (palopegteriparatide, a TransCon parathyroid hormone peptide analog for chronic hypoparathyroidism) delivered €252 million on consistent new patient demand in the US and continued ex-US global launch expansion with full reimbursement in additional markets. SKYTROFA (lonapegsomatropin, a TransCon growth hormone peptide for pediatric growth hormone deficiency) delivered €55 million. YUVIWEL (TransCon C-type natriuretic peptide for achondroplasia) delivered €8 million with more than 220 US patient enrollments through July 31, 2026. Total Q2 revenue reached €339 million (+100% YoY) including €24 million in collaboration and milestone income. The YUVIWEL launch positions Ascendis directly against BioMarin's Voxzogo (vosoritide) in the same achondroplasia pediatric indication, opening a new front in the CNP peptide analog commercial category. YORVIPATH's €252 million quarterly revenue trajectory suggests a $1+ billion annual run-rate for the peptide franchise by end of 2026, a notable rare-disease peptide launch magnitude. Ascendis's TransCon platform uses a transient linker chemistry to release parent drug over an extended half-life, allowing weekly dosing of peptides that natively have short in vivo lifespans.
Ascendis Pharma (Nasdaq: ASND) presented a subgroup analysis from the registrational ApproaCH trial of once-weekly TransCon CNP (navepegritide, brand name YUVIWEL) at ENDO 2026 in Chicago showing sustained annualized growth velocity (AGV) gains through two years of treatment in children 5 years and older with achondroplasia. Investigators reported significantly greater AGV at week 52 versus placebo with improvements sustained through year two. TransCon CNP was FDA-approved in February 2026 under the YUVIWEL brand to increase linear growth in pediatric patients 2 years of age and older with achondroplasia and open epiphyses. The C-natriuretic peptide prodrug is the second TransCon-platform asset approved after TransCon hGH (Skytrofa) for pediatric growth hormone deficiency.
Ascendis Pharma (Nasdaq: ASND) released June 11 the 5-year (Week 266) results from its Phase 2 PaTH Forward trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism, ahead of formal presentation at ENDO 2026 in Chicago. At Week 266, 82% of patients met the composite endpoint of normal serum calcium without active vitamin D and with less than 600 mg/day of calcium; nearly all participants achieved independence from conventional therapy, and 95% completed the full five years. TransCon PTH replicated endogenous PTH across kidney, intestine, CNS, and bone, with normalized urine and serum calcium, sustained bone mineral density, and quality-of-life gains. The data directly stress-tests MBX Biosciences's once-weekly canvuparatide Phase 2 readout from June 12, which posted 63% responder at 12 weeks and 57% at one year.